Blinatumomab bulk supplier for pharma manufacturers

Blinatumomab 35mcg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 35mcg

Reference Brands: Blincyto (USA/EU)

Blinatumomab is a bispecific T-cell engager (BiTE) antibody used in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). It works by connecting T-cells to cancerous B-cells, enabling the immune system to destroy them. Marketed under the brand name Blincyto, it is available as a powder for infusion (35 µg or 38.5 µg per vial). It is used in both adults and children with relapsed, refractory, or minimal residual disease–positive ALL.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Blinatumomab? List it or send an offer →

Product Description:

Blinatumomab is a bispecific T-cell engager: two antibody fragments joined together, one binding CD19 on B cells and the other CD3 on T cells. It does not kill cancer cells itself — it physically tethers a patient's own T cell to a leukaemic B cell, forming a synapse that activates the T cell to destroy it, regardless of the T cell's own antigen specificity.

It is used for B-cell precursor acute lymphoblastic leukaemia, including minimal residual disease positivity after chemotherapy, where clearing residual leukaemia improves survival. It is given as a continuous intravenous infusion over weeks, using a portable pump, because its half-life is only a few hours. Two toxicities define its use and both carry boxed warnings: cytokine release syndrome, from mass T-cell activation, and neurological toxicity with confusion, tremor and seizures. Treatment is started in hospital with stepwise dosing and corticosteroid premedication.

Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain. Continuous infusion over days means specific infusion bags, stabiliser solution and pump compatibility are part of the product, and preparation is exacting — pharmacy error in reconstitution has caused harm. Specialist haematology centres only.

Blinatumomab — third party manufacturing & bulk supply

Blinatumomab 35mcg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Blinatumomab is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Blinatumomab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Blinatumomab →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Blinatumomab is listed as Injection in 35mcg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Blinatumomab is referenced against Blincyto (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.